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doi:10.1016/j.kjms.2011.10.027Abstract Viral hepatitides are important public health problems in humans. The etiologic
agents were not identified until 1965, when Baruch S. Blumberg found the relationship of
Australia antigen to serum hepatitis. The antigen was found to be the surface antigen of
the hepatitis B virus (HBV). This observation launched a new era in the diagnosis, prevention
and treatment of hepatitis B. Over 15e20 years, the natural history of HBV infection was
elucidated, and more importantly, an effective vaccine became available. The routes of
transmission were also made clear, rendering effective interruption of the transmission
possible. The vaccine together with effective interruption of the transmission contributed
greatly to the control of HBV infection. However, these measures do very little for those
who have already been chronically infected. Fortunately, specific therapies against chronic
hepatitis B started to appear about 10e15 years before, and the treatments have improved
substantially in the last few years. Although far from perfect, effective means to treat those
who are chronically infected now exist. In Taiwan, acute and chronic liver diseases were
rampant as early as the beginning of the last century. Studies around 1975, showed
an extremely high prevalence of chronic hepatitis B infection in the general population
(15e20%), and 80e90% of the chronic liver diseases and hepatocellular carcinoma were
caused by chronic infection with the HBV. This important health problem caught the attention
of the government in the late 1970s, and a government-sponsored control program was final-
ized in 1981. Accordingly, a mass vaccination program against hepatitis B, primarily aiming at
immunizing newborn infants, was launched on July 1, 1984. Twenty years after implementa-
tion of the program, the hepatitis B carrier rate in children covered by the program decreased
by 85%, from w 15% to <1%. Most importantly, the deadly sequela of hepatocellular carci-
noma in the vaccinees was also found to decrease in parallel. This is the first time that
a human cancer was prevented by vaccination. Despite the success, there are still some
who were born after implementation of the program but were not prevented from developing
chronic hepatitis B infection and hepatocellular carcinoma. Non-compliance to thet of Internal Medicine, National Taiwan University College of Medicine, 1 Chang-Te Street, Taipei
w (D.-S. Chen).
vier Taiwan LLC. All rights reserved.
2 S. Wait, D.-S. Chenvaccination schedule, breakthrough infection and intrauterine infection are the causes of the
failure. At present, we have effective measures for immunizing susceptible individuals, inter-
rupting the routes of transmission and treating the chronically infected. The time for consid-
ering the elimination or even the eradication of HBV infection has come. This is especially
true for countries where hepatitis B infection is not endemic. Nevertheless, with the admi-
rable results achieved in the past, Taiwan should also think about elimination/eradication
of hepatitis B, even though it will certainly be much more difficult than in the non-endemic
countries. In exploring the possibility of eliminating/eradicating hepatitis B in Taiwan, we
reviewed the epidemiology of hepatitis B, and analyzed the problems that remain to be
tackled in Taiwan. We hope that Taiwan can take further steps towards the elimination or
eradication of hepatitis B.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
The hepatitis B virus (HBV) is the most common cause of
viral infection of the liver in the world. More than 2 billion
people worldwide have been infected with HBV and 75% of
all chronic HBV infections occur in Asia.
The virus is transmitted by contact with the blood or
body fluids of an infected person. In Asia, the main mode of
transmission is from an infected mother to her newborn
infant (mother-to-infant transmission). Other modes of
transmission, are child-to-child contact within households
where a family member is infected, contamination through
the reuse of unsterilized needles and syringes and sexual
transmission (homosexual and heterosexual).
The natural history of hepatitis B is complex, as it starts
off as an acute infection that may evolve into chronic
disease. Hepatitis B is often called a ‘silent disease’
because symptoms may remain absent for several years and
they are difficult to identify as they are not specific to
hepatitis.
When chronic hepatitis B does develop, it can lead to
serious and debilitating liver disease if left untreated,
including liver cancer. Liver cancer is the leading cause of
cancer in Taiwanese men and accounts for 21.8% of male
cancer deaths. It is the second-leading cause of cancer in
women and accounts for 14.2% of female cancer deaths.
Hepatitis B is a preventable disease. Taiwan was the first
country in the world to introduce a population-wide vacci-
nation programme against hepatitis B for all newborns in
1984. This programme has been extremely successful at
reducing the prevalence and mortality associated with HBV
in children. However, prevalence remains high in adults,
with>90% of the population having been infected with HBV
in the past. It is estimated that there are between 2.5 and
3 million carriers of HBV in Taiwan today.
For those infected with HBV, appropriate management
has been shown to substantially reduce the risk of long-
term liver damage, including cirrhosis and liver cancer.
Proper management of hepatitis B requires a combination
of the following:
(1) prevention: vaccination of newborns is the most
effective means of preventing hepatitis B. Targeted
prevention of groups at risk, accompanied by strong
educational campaigns, is also important; (2) screening of
individuals at risk. Given the absence of symptoms in the
early stages of hepatitis B, many individuals do not knowthat they are infected. Screening programmes are thus
necessary to contain the risk of infection by allowing indi-
viduals who are HBV-positive to follow the right course of
care for themselves, and to take appropriate measures to
avoid infecting others; (3) diagnosis and monitoring:
hepatitis B is under-diagnosed in Taiwan. Once diagnosis is
ascertained, it is critical that individuals are monitored
regularly to determine whether the disease has progressed
and whether treatment should be initiated; and (4) treat-
ment: there have been important advances in the devel-
opment of antiviral therapies to treat patients with
hepatitis B, as are reflected in recent clinical guidelines in
Asia and around the world. Early treatment is critical to
prevent the progression of liver disease.
Despite a successful vaccination campaign and the
existence of management options for patients infected
with HBV, hepatitis B remains under-diagnosed and under-
treated in Taiwan. Thousands of deaths/year are still
attributed to HBV today.
Thus complacency cannot be allowed to develop. Some
of the remaining challenges to achieving the optimal
containment, and eventual eradication, of hepatitis B in
Taiwan include the following.
Need for greater awareness and education: Govern-
ments, including local agencies, must continue extensive
screening programmes for hepatitis B and provide infor-
mation to help the general population better understand
the natural history of hepatitis B, the risks associated with
being an HBV carrier and the importance of appropriate
care. Efforts aimed at educating physicians are also crit-
ical, as many practitioners lack the necessary knowledge of
the best care to offer their patients.
Need to ensure continued success of the vaccination
programme: Careful quality control and monitoring of the
outcomes of the vaccination programme must remain
a public health priority for its success to continue. Further
research is also needed into the evolving epidemiology of
HBV in Taiwan to ensure that vaccination programmes are
not missing out on any new risk groups that may develop
over time.
Need to overcome geographic and social inequities in
access to care: Prevalence rates of HBV infection are
higher in indigenous populations, in persons of lower
socioeconomic status and in those living in remote areas.
Moreover, most hepatologists and gastroenterologists are
concentrated in the large urban centers and facilities for
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very limited in remote areas.
Need to improve standards of care: As in many clinical
areas, there is inconsistency in practice in the management
of hepatitis B. In particular, confusion remains around when
to initiate therapy and for how long. Careful monitoring
during treatment, using the most meaningful tests and
procedures available, is needed to continually evaluate the
efficacy of treatment and to adapt treatment over time to
prevent resistance to antivirals.
Need to remove financial barriers to care: Some of the
screening tests, diagnostic tests, procedures (including
liver biopsy) and antiviral therapies for hepatitis B do not
benefit from full reimbursement in Taiwan. Thus individuals
must often pay for them out-of-pocket. Costs may be
prohibitive and prevent individuals from receiving an
appropriate diagnosis, attending regular monitoring check-
ups or seeking and continuing treatment. Removal of these
financial barriers is essential if patients are to be offered
optimal care.
In summary: Hepatitis B continues to represent a tremen-
dous public health burden in Taiwan. Yet clinical experience
has shown that effective screening, diagnosis, monitoring
and treatment of individuals affected by HBV, can prevent
progression to severe liver disease in patients and thus lead
to a significant reduction in the burden of illness posed by
HBV on Taiwanese society. However, sufficient resources
are needed to ensure that individuals affected by HBV
receive the best care as early as possible. Concerted
actions amongst all stakeholders e policy-makers, health
professionals and patient representatives e are needed if
we hope to achieve the elimination and eradication of
hepatitis B from Taiwan in years to come.
Introduction: Hepatitis B in Taiwan
HBV is the most common cause of viral infection of the liver
in the world. More than two billion people worldwide have
been infected with HBV. Of these, more than 350 million
suffer from chronic HBV infection [1,2]. Chronic hepatitis B
is more prevalent than HIV (50 million cases worldwide) as
well as chronic hepatitis C (170 million cases worldwide).
Seventy-five percent of all chronic HBV infections occur
in Asia. The prevalence in Taiwan is 15e20% and >90% of
the adult population has been infected with HBV in the
past. It is estimated that there are between 2.5 and 3
million carriers of HBV in Taiwan today [3]. HBV carriers are
at risk of transmitting the virus to others. Also, they face an
absolute lifetime risk of death from liver-related diseases,
including cancer, of 15e20% [4]. Indeed, hepatitis B is the
main cause of liver cancer, which is in turn the most
frequent cause of cancer in Taiwan [5].
Taiwan was the first country in the world to introduce
a population-wide vaccination programme against hepatitis
B starting from all newborns in 1984. This programme has
been extremely successful at reducing the prevalence and
mortality associated with HBV in children. However,
detectable virus remains a concern within the adult pop-
ulation and prevalence rates have not decreased in adults
over the age of 18 since the onset of vaccination [6]. Thus,
the burden posed by hepatitis B on society and on healthcare resources is likely to prevail for the considerable
future [7].
For those infected with HBV, appropriate management
has been shown to substantially reduce the risk of long-
term liver damage, including cirrhosis and liver cancer.
However, a large proportion of HBV-infected individuals do
not access appropriate and timely diagnosis, monitoring or
treatment in many countries of the world, including
Taiwan. This is due to a number of factors, the most
important of which is low awareness of the urgency to seek
medical advice about hepatitis B in the general population.
This is compounded by incomplete knowledge, by treating
physicians, of the most appropriate management options
for patients and financial barriers due to limited reim-
bursement of diagnostic and treatment alternatives. Thus
much remains to be done to minimize the burden of illness
posed by hepatitis B on Taiwanese society.
The purpose of this document is to present an up-to-date
summary of the main facts surrounding the prevalence,
mortality, natural history, and management of hepatitis B
in Taiwan, to raise public awareness, and to provide
a platform for discussion amongst patient representatives,
leading scientific experts and policy-makers. It is hoped
that this will assist all stakeholders to identify the key
challenges and opportunities to be addressed, if we are to
move one step closer towards the elimination and eradi-
cation of hepatitis B infection in Taiwan.
What is hepatitis B?
HBV is the most common of the viruses (A, B, C, D and E)
that cause hepatitis, which means inflammation of the liver
[8]. Hepatitis B is transmitted by contact with the blood or
body fluids of an infected person. Unlike hepatitis A or E, it
cannot spread through contaminated food or water.
The virus survives out of the body for up to 7 days, thus
the risk of infection upon exposure is very high. In fact, the
virus is 100 times more infectious than HIV and 10 times
more infectious than hepatitis C.
Who is at risk of becoming infected? The main modes of
transmission are: (1) vertical e when an infected mother
transmits it to her child at birth; and (2) horizontal e health
care workers exposed to sharp objects; sexual contact
(heterosexual or homosexual) with infected individuals;
shared contaminated needles amongst injection drug users;
household contacts of chronically infected persons.
In Asia, the main route of transmission of HBV is from an
infected mother to her newborn infant (mother-to-infant
transmission). Other major modes of transmission are child-
to-child contact within households where a family member
is infected and contamination through the reuse of
unsterilized needles and syringes in healthcare settings [8].
Natural history: The natural history of hepatitis B is
complex, as it starts off as an acute infection that may
evolve into chronic disease. Most cases of acute hepatitis B
will resolve naturally without treatment. However, when
chronic hepatitis B develops, it can lead to serious and
debilitating liver disease if left untreated (Fig. 1).
The risk of developing chronic disease depends on the
age at which one becomes infected. Around 90% of indi-
viduals who are infected as newborns will develop chronic
Figure 1. The natural history of hepatitis B. Adapted from Torresi et al., 2000 [11] and Fattovich et al., 2003 [12].
Table 1 Incidence of the five leading types of cancer in
Taiwanese men, 2005 [3]
Site of cancer No. of
new cases
in 2005
Crude
incidence
(per 100,000)
Liver and intrahepatic bile ducts 7,159 62
Colorectal 5,497 48
Lung, trachea and bronchus 5,566 48
Oral cavity, oropharynx
and hypopharynx
4,310 37
Prostate 2,704 23
4 S. Wait, D.-S. ChenHBV infection, whereas this risk is much lower if one is
infected as a child younger than 5 years of age (25e30%) or
as an adult (1e5%). For this reason, the main focus of
vaccination programmes against HBV has been amongst
newborns and children.
A silent disease: Hepatitis B is often called a ‘silent
disease’ because symptoms are difficult to identify as they
are not specific to hepatitis. They include loss of appetite,
tiredness, vomiting, fever, joint pain, nausea, abdominal
pain and jaundice. Even at the chronic stage of disease,
many people are unaware of any symptoms.
Chronic hepatitis B may best be described as an evolving,
dynamic set of interactions over time between the virus
itself, cells in the liver (hepatocytes) and the person’s
immune system [9,10]. The nature of these interactions
defines the natural course of hepatitis B in several different
phases. For persons infected at birth or during early child-
hood, there is usually a long initial phase termed the
‘immune tolerant phase’ during which the person does not
exhibit any symptoms and the liver is not yet damaged.
The duration of these different phases, however, will
vary from one individual to another. For this reason, it is
critical that all persons known to be HBV-positive be
monitored carefully, so that appropriate steps may be
taken to manage their disease as effectively as possible
over the course of time.
Liver cancer: Once chronic disease starts causing liver
damage, its consequences can be very serious. As is shown
in Fig. 1, 30% of patients with chronic infection develop
cirrhosis and nearly half of them will die from liver failure
or liver cancer (more accurately referred to as hepatocel-
lular carcinoma or HCC).
Hepatitis B remains the main cause of liver cancer in
Taiwan, followed very closely by hepatitis C [13]. Liver
cancer is the leading cause of cancer in Taiwanese men and
accounts for 21.8% of male cancer deaths. There were an
estimated 7159 cases of liver cancer in men in 2005, which
represents an incidence of 62 new cases/100,000 men every
year (Table 1). Liver cancer is somewhat less frequent in
women, in whom it is the second-leading cause of cancer
mortality (2757 cases in 2005 and 14.2% of female cancer
deaths) [3,13].Chronic liver disease and cirrhosis are the seventh most
important causes of death in Taiwan. It is estimated that
close to 11,000 people die every year in Taiwan due to liver
failure or cirrhosis related to HBV [7].
A significant economic burden: In addition to its impact
on morbidity and mortality, hepatitis B also poses a signifi-
cant economic burden on society. Direct costs include the
cost of treatment for acute and chronic hepatitis, cirrhosis,
and liver cancer. Indirect costs result from lost productivity
of patients with HBV in terms of the time they need to
receive treatment or spend in hospital, time off work due
to illness and premature death due to the sequelae of
hepatitis B. As one would expect, costs increase signifi-
cantly with progressively worsening disease state.
Most patients with sequelae of hepatitis B occur
between 30e50 years of age. Therefore, a large number of
people affected by hepatitis B are men of working age, who
are very likely the sole supporters of their families. Their
illness can thus have a significant economic impact on their
family’s welfare.
Managing hepatitis B disease: prevention,
screening, monitoring and treatment
Proper management of hepatitis B requires a combination
of prevention, screening of individuals at risk, monitoring
of HBV-positive individuals to decide when to initiate
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A necessary companion to each of these aspects of
management is thorough education and information of
patients, their families and treating physicians to ensure
that the optimal care is chosen for each individual affected
by HBV infection.
Vaccination: the most effective prevention: Hepatitis
B is a preventable disease. Because mother-to-infant
transmission is the most important route of transmission,
the most effective prevention method is vaccination of
newborns and young children. A vaccine against HBV has
existed since 1982 and HBV was included in the World
Health Organization Expanded Programme on Immunization
(EPI) programme in 1991. Today, over 130 countries offer
systematic vaccination to newborns against HBV.
Taiwan was the first country to introduce a universal
vaccination programme against HBV in 1984 [14]. The pro-
gramme has evolved over the years, and today, it covers all
newborns, who receive a vaccine dose at 0, 1 and 6 months.
Catch-up vaccinations are also given to all preschool chil-
dren who did not receive vaccination at the neonatal
period, to all first-graders and all children <15 years of age.
Coverage of infants is in the order of 97% [15]. Vaccination
is also offered to all susceptible health-care workers [7].
As a result of the vaccination programme, the rate of
chronic hepatitis B infection amongst children in the Taipei
City under the age of 15 years has decreased from 9.8% in
1984 to 0.7% in 1999 [15]. The liver cancer rate in children
aged 6e14 years has fallen from 0.7/100,000 in the early
1980s to 0.36/100,000 in the early 1990s [16]. Moreover, the
vaccination programme has resulted in decreased rates of
horizontal transmission amongst children [17].
Targeted prevention of high-risk groups: Other
prevention efforts exist to encourage individuals at risk to
modify their behaviors, to minimize their risk of becoming
infected by HBV. Tactics include promoting condom use to
avoid sexual transmission (heterosexual and homosexual),
implementing safe syringe use and sharps disposal for
medical personnel, and providing needle-exchange pro-
grammes to intravenous drug users.
Screening: Screening for HBV is a critical means of
identifying individuals who are at high risk of being infected
by HBV but do not present any symptoms (asymptomatic
HBV carriers), to ensure that they receive appropriate
monitoring, treatment and counseling, and that they do not
unknowingly infect others. Given that universal vaccination
was only introduced in 1984, individuals born before that
time are still at high risk of carrying the HBV. Screening is
the only way to ensure that all cases of HBV infection are
identified before diseases become apparent.
To be successful, screening programmes must be accom-
panied by appropriately targeted public information
campaigns, to ensure that individuals follow up screening
with necessary actions.
Screening policies for HBV differ significantly from
country to country. In Taiwan, screening is done at blood
donation, when entering school, the military or new
employment. In China, children and adolescents are
screened before admission to kindergarten, school and
university, and hospitalized patients are all screened
systematically for HBV markers. In Singapore, all persons
applying for residential virus are screened [7].Diagnosis: Identification of HBV is done by various tests,
where one looks for hepatitis B viral or serological markers
(signs for HBV in the blood).
Unfortunately, a great majority of HBV patients remain
undiagnosed, mostly because of the silent nature of hepa-
titis B. In addition, many diagnostic and monitoring tests
are not reimbursed in Taiwan. Therefore, inability to pay is
often an obstacle to receiving appropriate care for many
poorer patients with hepatitis B [7]. This is particularly true
in the case of recent molecular assays. Additionally, many
physicians seeing individuals who are carriers for HBV may
not be fully aware of the most effective diagnostic and
monitoring tests available [18]. Finally, individuals who
suspect they are infected with HBV may be reluctant to
seek diagnosis for fear of stigmatization.
Monitoring: Diagnosis is the first step towards appro-
priate management of HBV, however, initial diagnosis
must be followed by continuous monitoring of the patients’
viral load, to determine whether treatment is needed, at
what point it should be initiated and for how long. These
questions remain critical issues of discussion among
leading experts of hepatitis B in Taiwan and elsewhere in
the world [19].
Monitoring is done via periodic assessment of key
parameters such as HBV DNA levels, as well as liver disease
progression. The critical role of HBV DNA as a marker for
liver cirrhosis as well as liver cancer was ascertained in
world-acclaimed studies conducted mainly in Taiwan
[20,21]. The conclusions of these studies have allowed for
much greater precision in determining at what point to
initiate antiviral treatment for HBV-infected patients and
whether treatments administered are being effective.
The most recognized means of identifying the stage of
progression of liver disease is liver biopsy. Yet, many
patients are reluctant to undergo liver biopsy for fear of the
invasiveness of the examination.
Existing guidelines offer recommendations as to the
most meaningful markers and the most effective moni-
toring techniques [22]. However, practice varies signifi-
cantly and patients may fail to present for annual
monitoring check-ups in the absence of symptoms. As
a result, they may only present to physicians for treatment
at a stage when cirrhosis or extensive liver damage has
already begun. The fact that many monitoring tests are not
comprehensively reimbursed in Taiwan, poses an additional
financial hurdle to appropriate patient management.
Treatment: The ultimate goal of HBV treatment is to
permanently inhibit replication of the HBV, as this has been
shown to be the most important factor in reducing the risk
of long-term liver damage and progression to cirrhosis and
liver cancer. It is thus critical to initiate treatment early,
using the most meaningful markers for viral replication to
prevent significant liver damage from occurring. Early
treatment also allows preventing the significant health
care costs associated with subsequent advanced liver
diseases.
Treatment options: The past few decades have seen
tremendous advances in the discovery of effective and safe
antiviral agents against HBV. Two main antiviral treatment
options exist currently: interferon-a, and nucleoside/
nucleotide analogues. Interferon is given by injection,
whereas nucleoside/nucleotide analogues are administered
6 S. Wait, D.-S. Chenorally. Because of the high prevalence of HBV infection in
Asia, many of the clinical trials testing these medicines
have taken place in Asia in Asian patients. Thus, significant
experience has been gained that has demonstrated the
ability of antiviral treatments to stop viral replication,
prevent the occurrence of cirrhosis, and reduce mortality in
patients affected by chronic hepatitis B [18]. Studies have
also shown that effective therapies against HBV may reduce
the healthcare costs associated with chronic hepatitis B in
Taiwan [23].
An evolving evidence base: As in other therapeutic
areas, evidence and knowledge about the effectiveness of
different treatment approaches is constantly evolving. At
the same time, important insights into the natural history
of hepatitis B have been gained in recent years.
On the basis of this combined evidence, experts from
around Asia have written a consensus statement on the
management of chronic hepatitis B, the most recent version
being updated in 2008 [22]. These guidelines look in depth
at which particular treatments are most appropriate for
specific groups of patients in accordance with their viral
load tests, liver function tests and other clinical parame-
ters. They also provide guidance as to which treatments
should be initiated when, and for how long.
Under-treatment: Despite the emergence of these
guidelines, too few patients actually benefit from treat-
ment in Asia, including Taiwan. An international survey
estimated that only 4% of patients diagnosed with HBV in
Asia received treatment, as opposed to rates of 20% in the
United States and 17e28% in Europe.
These low treatment rates are due to many factors.
These include: low awareness amongst carriers as to the
need for monitoring, insufficient knowledge on the part of
physicians of the importance of timely treatment and
financial barriers in access to treatment in Taiwan.
Complex disease management: As has been described
above, the pathways of care for hepatitis B are complex.
Many health professionals may not have had the oppor-
tunity to fully understand the management options
available to patients infected with HBV. Yet, this knowl-
edge is essential if patients are to be offered the indi-
vidualized counseling, assessment and explanation of care
options necessary to optimize their chances of successful
outcomes [22].
Recognition of the need for dedicated training on
hepatitis B was a key driver behind the recommendations
of the Asian Pacific Association for the Study of the Liver
(APASL). Also, a number of helpful pocket guide books
[24,25], journal supplements and internet-based outreach
educational programmes have been developed in Taiwan
to try to help primary care physicians, internists, gastro-
enterologists and hepatologists, to improve the standard
of care offered to patients infected with HBV [18].
Financial barriers to treatment: Only some of the
antiviral therapies advocated in the APASL guidelines,
benefit from full reimbursement in Taiwan [18]. As a result,
patients must pay for treatment out-of-pocket. Only a very
small minority of patients have private insurance to cover
full treatment costs. Fortunately, the Bureau of National
Health Insurance has recently lifted some key hurdles in
financial barriers, and the improvements are anticipated.Challenges to containing hepatitis B in Taiwan
A huge success story: The Taiwanese vaccination pro-
gramme against hepatitis B is a true success story. It is also
a promising example of how many diverse institutions e the
local governments, the Department of Health, the Ministry
of Education, the Ministry of National Defence, academic
institutions, non-profit organizations and local government e
can work together to achieve a common public health goal.
The programme was also made possible thanks to
a strong public health infrastructure, highly trained nurses
and an active public education campaign that took place
for at least 3 years before the onset of vaccination in 1984.
Moreover, Taiwan has also made important efforts to
improve the management of patients infected with HBV. In
2003, the Taiwanese Center for Disease Control initiated
a pilot programme entitled ‘Strengthening of treatment for
chronic hepatitis B and C under the National Health Insur-
ance’. The programme tries to ensure that all cases of
hepatitis B (andhepatitis C) are registered, so that individuals
affected may benefit from appropriate diagnosis, monitoring
and treatment. The ultimate goal of the project is to reduce
the incidence of liver cirrhosis and liver cancer in Taiwan.
Finally, the comprehensive disease registry and death
certification system in Taiwan have helped identify and
monitor cases of hepatitis mortality and liver cancer in
children over the years and evaluate the success of the
vaccination programme [17].
Yet challenges remain: Despite this success, hepatitis B
remains a major public health problem in Taiwan, resulting
in thousands of deaths/year. Moreover, a number of studies
have shown that general awareness of hepatitis B remains
inadequate within the Taiwanese population, despite
repeated public educational efforts on behalf of the
Taiwanese government. For example, a survey of 1025
adults aged 30 years and above in Taiwan found that only
52% knew about chronic HBV infection and only 46% knew of
the existence of effective treatments. Fewer than half of
individuals infected with chronic hepatitis B knew that they
were infected [26]. Similar results were found in Taiwanese
university students, with several studies finding that up to
one-quarter of students who were HBV-carriers were
unaware of their status or of the necessary actions they
needed to take to prevent disease from developing over
time and to avoid infecting others [27,28]. These worrying
results are not unique to Taiwan and are a sobering
reminder of the lack of knowledge about HBV in the general
population and the need for greater efforts to use settings
such as universities and schools to help raise awareness of
the disease.
Thus complacency cannot be allowed to develop, and
further efforts to ensure that appropriate prevention,
screening, diagnosis and treatment are offered to the
entire population, are still urgently needed.
Some of the remaining challenges to achieving the
optimal containment, and eventual eradication, of hepa-
titis B in Taiwan include:
Need for greater awareness and education: Need for
greater emphasis on the importance of screening and
regular monitoring of HBV: Screening for hepatitis B is
critical to ensure that all individuals infected by HBV
Figure 2. Pathways for HBV infection and steps towards
eradication of HBV. Adopted from Chen 2009 [32].
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behaviors and seek appropriate care. Governments,
including local agencies, must continue extensive screening
programmes for hepatitis B. In addition, significant efforts
are needed to ensure that individuals infected with HBV are
monitored regularly for disease progression using the most
meaningful tests and procedures and that physicians are
aware of protocols to be followed and optimal tests and
techniques to be used.
Inadequate understanding of hepatitis B amongst
treating physicians: Many practitioners have inadequate
knowledge to identify individuals at risk of infection, thus
hepatitis B remains under-diagnosed in Taiwan. It is also
under-treated, as many physicians lack sufficient knowl-
edge of the pathways of care that are available to patients
infected with HBV, limiting their ability to offer individu-
alized advice to their patients. The importance of early
treatment in particular needs to be recognized [22].
Poor understanding of hepatitis B in the general
population: Hepatitis B is a complex disease. Under-
standing its natural history, the risks associated with being
an HBV carrier, and the importance of appropriate care,
requires dedicated educational efforts specific to each risk
group. There have been a number of public awareness
campaigns in Taiwan, yet further efforts are needed,
particularly to encourage individuals to undergo screening.
Also, it is important to recognize that the stigma about
being HBV-positive may inhibit certain individuals from
seeking appropriate screening, as they fear discrimination
within their communities and possible repercussions on
their employment status if they are known to be HBV-
positive [29]. This fear may also make them reluctant to
undergo diagnosis and appropriate care.
Need to ensure continued success of the vaccination
programme: Continuous evaluation of the quality and
impact of vaccination: Continued success of the vaccina-
tion programme in Taiwan requires the availability of high-
quality vaccines, prevention of vaccine failure and careful
monitoring of outcomes of vaccination. These must remain
a public health priority for the public health impact of the
HBV vaccination programme to continue in Taiwan [13,30].
Adapting to a changing epidemiology of HBV: Further
research is needed into the natural history and evolving
epidemiology of HBV in Taiwan, to ensure that vaccination
programmes are not missing any new risk groups that may
develop over time. For example, although waning immunity
of the vaccine after 15e20 years has not yet been observed
to the extent that a booster is generally recommended
after this time period, the possibility that this situation may
change should be monitored closely.
Need to improve standards of care for the manage-
ment of hepatitis B: Lack of compliance with clinical
guidelines: As in many other clinical areas, there is
inconsistency in practice in the management of hepatitis B.
Continuing educational efforts are needed to disseminate
the 2008 revised APASL guidelines and ensure that care is
harmonized across different treatment centers. In partic-
ular, decisions about when to initiate therapy, and for how
long, should be based on the most up-to-date evidence, as
there remains considerable uncertainty as to what the
optimal duration of antiviral therapy should be in different
groups of HBV-infected patients.Resistance issues with many antivirals: An issue
which has already emerged with the use of some of the
antivirals, particularly the older ones, is that the HBV
may become resistant to some of these drugs, particu-
larly after prolonged treatment. Thus, careful monitoring
during treatment is needed to adapt treatment over
time. Many of the newer antivirals do not seem to
exhibit the same resistance patterns as some of the older
agents [10].
Need to overcome geographic and social inequities in
access to care: Higher prevalence of hepatitis B infection
in vulnerable populations: Despite vaccination, preva-
lence rates of hepatitis B infection are higher in indigenous
populations, in persons of lower socioeconomic status, as
well as those living in remote areas [31]. Particular
prevention, screening and monitoring efforts are thus
needed with these difficult-to-reach populations.
Lack of medical clinics in rural areas: In Taiwan, as in
many Asian countries, there are limited facilities offering
diagnosis, screening and treatment for HBV in rural areas.
Moreover, most hepatologists and gastroenterologists are
concentrated in the large urban centers. Thus, innovative
ways to provide targeted outreach programmes to individ-
uals residing in these remote areas are needed.
The way forward
Twenty-six years after the introduction of its vaccination
programme against hepatitis B, Taiwan is at an exciting
juncture with respect to hepatitis B. More than any other
country, it can realistically contemplate the possibility of
eliminating and eradicating the disease from its population,
perhaps within the next 50 years.
Eradication of hepatitis B in Taiwan will require
concerted efforts in a number of key areas. As was stated
by Professor DS Chen:
Eradication of hepatitis B in Taiwan requires ‘long-term
commitment to continue the vaccination as well as inter-
rupting the routes of transmission, treating the chronic
HBV carriers, so that the infection is completely stopped.’
[32].
These three areas of focus are illustrated in Fig. 2.
Firstly and foremost, susceptible individuals must be
immunized. The continued success of the vaccination pro-
gramme should not be taken for granted and continued
efforts to achieve high coverage levels, and monitor the
8 S. Wait, D.-S. Chenoutcomes of the vaccination programme on the epidemi-
ology of HBV in Taiwan, are needed.
Secondly, the actual source of infection should be sup-
pressed to a maximal extent. In other words, HBV-infected
individuals should be treated in order to reduce the viral
load of HBV to undetectable levels, to prevent the spread of
infection. For this to occur, rates of diagnosis, monitoring
and treatment need to increase significantly in Taiwan.
Most importantly, barriers in access must be removed to
ensure that individuals affected by HBV are properly iden-
tified, that their disease is carefully monitored, and that
they receive timely and appropriate treatment.
Thirdly, routes of transmission must be interrupted.
Primary prevention measures targeted at high-risk individ-
uals need to be implemented and compliance with such
measures encouraged through public awareness campaigns.
Targeted screening programmes are needed across the
entire population.
In conclusion, hepatitis B continues to represent
a tremendous public health burden in Taiwan. It is the main
cause of liver cancer, which in turn is the leading cause of
death in men and the second cause of death in women. Yet,
clinical experience has shown that effective screening,
diagnosis, monitoring and treatment of individuals affected
by HBV, can lead to a significant reduction in the burden
of illness posed by HBV, and prevent progression to
severe liver disease in patients. If sufficient resources are
devoted to continuing vaccination and improving access
to screening, diagnosis and treatment for hepatitis B in
Taiwan, then complete eradication of hepatitis B may
indeed be a long-term possibility. In the meantime,
concerted efforts are warranted to minimize the burden of
hepatitis B on Taiwanese society and ensure that individuals
affected by HBV achieve the best outcomes possible.Acknowledgments
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